[Stitcher]

as I was beginning to have...hence, CERE-120...crossing my fingers

SoloSTAR(R), The First Prefilled Disposable Insulin Pen For Lantus(R), Is Now Available In The United States
Main Category: Diabetes News
Article Date: 31 Jul 2007 - 0:00 PDT

Read full article: http://www.medicalnewstoday.com/articles/78295.php

Sanofi-aventis announced today that Lantus(R) SoloSTAR(R), a new, disposable insulin pen is now available. The SoloSTAR(R) pen offers people with diabetes a more convenient option for taking their insulin than through traditional methods. The SoloSTAR(R) pen is prefilled with Lantus(R) (insulin glargine [rDNA origin] injection), the only 24-hour insulin approved exclusively for use once a day, for the treatment of hyperglycemia in people with type 1 or type 2 diabetes.

SoloSTAR(R) is the only prefilled disposable insulin pen that allows patients to administer doses from 1 up to 80 units, in one injection. SoloSTAR(R) offers a 25% greater maximum capacity than other insulin pens.

"Lantus(R) has been proven to help lower blood sugar levels and can help patients reach their goals," said Stephen N. Davis M.D., FRCP, Mark Collie Professor of Medicine, Molecular Physiology and Biophysics, Chief of Diabetes, Endocrinology and Metabolism, Vanderbilt University, "Now, with the addition of the Lantus(R) SoloSTAR(R) pen, patients will find that the new pen is easy to use and will make Lantus(R) delivery even more convenient."

SoloSTAR(R) operates with a lower injection force and a recent study found that SoloSTAR(R) required 31% less injection force than the Novo Nordisk FlexPen and 54% less force than the Eli Lilly Humulin/Humalog pen. Similar results have been observed in a second study.

"Insulin pens are underutilized in the United States as compared to other countries, even though they may offer more convenience and flexibility for people with diabetes," said Angela Moskow, associate vice president, Diabetes Marketing, sanofi-aventis. "Lantus(R) SoloSTAR(R) demonstrates sanofi-aventis' commitment to designing devices based on insights from people with diabetes, to help meet their lifestyle demands. We are excited to offer this new device."